BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

Rachel Humphrey has joined Black Diamond Therapeutics Inc. (NASDAQ:BDTX) as CMO. Karsten Witt, who has been SVP of clinical development and acting CMO since May 2019, will become SVP of non-clinical development. Previously, Humphrey was...
BioCentury | Nov 16, 2018
Company News

Google Brings Geisinger CEO on Board to Focus on Healthcare

Beyond a quick mention of Verily Life Sciences LLC and AI, Google Inc. is saying little about what it plans to do with its healthcare initiatives now that David Feinberg is leaving Geisinger Health System...
BioCentury | Nov 10, 2018
Company News

Google brings Geisinger CEO on board to focus on healthcare

Beyond a quick mention of Verily Life Sciences LLC and AI, Google Inc. is saying little about what it plans to do with its healthcare initiatives now that David Feinberg is leaving Geisinger Health System...
BioCentury | Feb 10, 2018
Finance

Foundation validation

...eras of CF treatment. In the 1990s, CFF contributed funding to develop the inhaled antibiotic TOBI...
BioCentury | Feb 6, 2018
Politics & Policy

EU court upholds EMA's decisions on transparency

...AG (NYSE:NVS; SIX:NOVN), which had already received EU approval -- and market exclusivity -- for TOBI...
BioCentury | Aug 16, 2017
Politics & Policy

Gorsky reverses course; Trump councils disband

Within minutes of each other on Wednesday, Johnson & Johnson (NYSE:JNJ) CEO Alex Gorsky changed his decision and resigned from President Trump's White House Manufacturing Advisory Council, while the president said in a tweet that...
BioCentury | May 19, 2017
Finance

Breathe in, cash out

...played a leading role in the development of four FDA approved aerosol drugs -- including TOBI...
BioCentury | May 1, 2017
Company News

Cleveland Clinic's Cosgrove to step down

Cleveland Clinic said Toby Cosgrove will step down this year as president and CEO. The clinic has asked Cosgrove to continue on in an advisory role. Its boards of directors and governors expects to select...
BioCentury | Mar 3, 2014
Product Development

Pause for breath

Efficacy data for InterMune Inc. 's Esbriet pirfenidone are likely to be enough for U.S. approval to treat idiopathic pulmonary fibrosis, but doctors contacted by BioCentury said it may only add weeks to patient lives...
BioCentury | Mar 3, 2014
Clinical News

Arikace amikacin: Extension study data

...data from CLEAR-108 showing Arikace met the primary endpoint of non-inferiority to twice-daily 300 mg TOBI...
...of Transave Inc. (see BioCentury, Dec. 6, 2010). Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets TOBI...
Items per page:
1 - 10 of 175